Aurorium Introduces Haelium Pharmaceuticals For Next-Generation Treatments

Jenny Titova, Strategic Marketing Manager — pharmaceutical, “The launch of the Haelium brand will more clearly represent our position in the pharmaceutical space - a global leader dedicated to enhancing drug efficacy through high-purity solutions and drug delivery products.”

The Haelium brand offers a range of advanced solutions, including high-purity buffers, reagents, solvents, extended-release coatings, and immunostimulants. These products cater to various therapeutic areas such as peptide and oligonucleotide production, large molecule biologics, vaccines, and oral solid dosage forms.

Haelium operates from four state-of-the-art manufacturing sites in North America, all compliant with Current Good Manufacturing Practice (cGMP) standards. Their facilities are equipped with advanced purification capabilities and supported by robust regulatory expertise, ensuring high-quality standards across their product range.

Dr. Steve Tattum, Vice President of Specialy Solutions, “As we continue to innovate in response to emerging trends in healthcare, investing in the pharmaceutical space emphasises our commitment to improving patient outcomes. With these strategic investments, we aim to support groundbreaking research and development that will shape the future of medicine and advance global health. From the inception of novel ideas to product launches, our priority is to fuel our customer’s success by partnering to solve their challenges.”

Building on Aurorium's legacy as a specialty ingredient manufacturer in the pharmaceutical sector, Haelium blends innovation and manufacturing expertise to create practical solutions that support the healing process of patients globally.